09/27/2023
https://congress.gov...
"But that is quite all right, thank you. Thankfully, we do know, and the answer is that it was."
"So, Mr. Schultz, why is the price of Copaxone so much higher for people with multiple sclerosis in the United States than those in other countries?"
"And while Teva was forced to put pressure, was forced to lower the price in Europe, in that same two-year period, the company raised the price on U.S. multiple sclerosis patients by 60 percent."
"Even with charging those lower prices, does Teva turn a profit in Europe?"